Exane BNP Paribas analyst Andrew Grobler upgraded Rentokil Initial to Neutral from Underperform with a price target of 555 GBp, up from 470 GBp. The analyst sees "no clear negative catalyst" for the shares and notes improvement in several areas of previous concern.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RTO:
